Q&A with Shield Therapeutics Founder and CEO, Carl Sterritt
After the release of clinical trial results sparked an over 20% increase in share price, Shield's Founder CEO Carl Sterritt stopped by our offices to tell us exactly what the study showed about their leading asset Feraccru and what impact it will have on both the company and patients.
Carl emphasised how Feraccru, now proven to be equivalent to its intravenous counterparts, gives patients the opportunity and freedom to treat their iron deficiency in a simpler, more cost effective way.
Tune in as Carl also walks us through Shield Therapeutics' other major projects coming to market, as it exemplifies how this clinical trial was only the beginning.
For more news and updates on Shield Therapeutics:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.